Pediatric Exclusivity Sales Triggers May Be Proposed In Senate Mark-Up
Executive Summary
Proposals to tie the length of pediatric exclusivity to product sales raise questions about FDA's ability to track commercial performance, Sen. Dodd (D-Conn.) said during a May 8 hearing of the Senate Health Committee.
You may also be interested in...
Pediatric Drug Exclusivity Reauthorization Expected In House Before August
Legislation reauthorizing pediatric exclusivity for drugs is expected to be introduced in the House by Rep. Greenwood (R-Penn.) before Congress' August recess.
Pediatric Drug Exclusivity Reauthorization Expected In House Before August
Legislation reauthorizing pediatric exclusivity for drugs is expected to be introduced in the House by Rep. Greenwood (R-Penn.) before Congress' August recess.
Pediatric Labeling Negotiations Limited To 6 Months In Reauthorization Bill
Negotiations for pediatric labeling changes would be limited to six months under a proposed bill to reauthorize the pediatric exclusivity provisions.